Preclinical evaluation of KZR-261, a novel small molecule inhibitor of Sec61

Kezar Life Sciences, Inc.

American Society of Clinical Oncology (ASCO 2020)

Blocking Protein Secretion With Novel Small Molecule Inhibitors of Sec61 Represents a Potential Treatment Strategy Against Hematologic Malignancies

Kezar Life Sciences, Inc

American Society of Hematology (ASH 2019)

Proteomic Profiling and Mechanistic Investigating of a Novel Anti-cancer Small Molecule Inhibitor of Sec61

Kezar Life Sciences, Inc

American Society of Hematology (ASH 2019)

Treatment of Sle Patients With the Immunoproteasome Inhibitor Krz-616: Results From the First 3 Cohorts of an Open-label Phase 1b Dose Escalation Trial

Kezar Life Sciences, Inc

American College of Rheumatology (ACR 2019)

Profiling of Gene Expression, Immune Cell Subtypes, and Circulating Protein Biomarkers in Systemic Lupus Erythematosus Patients Treated With the Selective Immunoproteasome Inhibitor, Kzr-616

Kezar Life Sciences, Inc

American College of Rheumatology (ACR 2019)

Safety, Pharmacokinetics, and Pharmacodynamics of a Lyophilized Drug Product of Kzr-616, a Selective Inhibitor of the Immunoproteasome

Kezar Life Sciences, Inc

American College of Rheumatology (ACR 2019)

Selective Inhibition of the Immunoproteasome With Kzr-616 Blocks Multiple Cell Signaling Pathways, Plasma Cell Signatures and Myeloid Cell Associated Damage in the Nzb/w Lupus Nephritis Model

Kezar Life Sciences, Inc

Targeting Multiple Immune Checkpoint Proteins With Novel Small Molecular Inhibitors of Sec61-dependent Cotranslational Translocation

Kezar Life Sciences, Inc

The Pharmacokinetic Differences Between Humans and Animals of KZR-616, a First-In-Class, Selective Immunoproteasome Inhibitor, In Two Clinical Formulations

Kezar Life Sciences, Inc

Treatment of Systemic Lupus Erythematosus Patients with the Immunoproteasome Inhibitor KZR-616: Results from the First 2 Cohorts of an Open-label Phase 1b Dose Escalation Trial

Kezar Life Sciences, Inc